<![CDATA[Hemorrhagic stroke is a subtype of stroke with high mortality and morbidity, frequently accompanied by cerebral edema, making rational anti-cerebral edema therapy essential for improving clinical outcomes. This study aimed to evaluate the rationality of anti-cerebral edema drug use and analyze factors associated with the clinical outcomes of hemorrhagic stroke patients at Dr. Moewardi Regional General Hospital, Surakarta. This retrospective analytical observational study used medical records of 86 patients with intracerebral hemorrhagic stroke selected through consecutive sampling. The rationality of therapy was evaluated based on the 2019 Indonesian National Guidelines for Stroke Management (PNPK) and the 17th edition of the Drug Information Handbook (DIH), while clinical outcomes were assessed using the Glasgow Coma Scale (GCS). Data were analyzed using the Chi-Square test and logistic regression. The results showed that 52.3% of patients were male and 47.7% were female. Rational anti-cerebral edema therapy was identified in 83.7% of patients, whereas 16.3% received irrational therapy due to inappropriate dosage (9.3%) and inappropriate drug selection (7.0%). No significant association was found between the rationality of drug use and clinical outcomes (p = 0.327). However, multivariate analysis demonstrated that an admission GCS score of less than 8 was the strongest predictor of poor clinical outcomes (OR = 13.578; 95% CI: 3.179–57.995; p < 0.001). In addition, the use of mannitol and furosemide was significantly associated with patients’ clinical outcomes.]]>
Copyrights © 2026
